INS webinars deliver the most current infusion-related topics in a 60-minute presenter-led session. Each webinar is delivered live and then archived for on-demand viewing. All webinars are free to INS members.

Webinars

Search by Format
Sort By
Search by Favorites
Search by Keyword

  • Targeting FcRn in generalized myasthenia gravis with RYSTIGGO® (rozanolixizumab-noli)
    Contains 3 Component(s), Includes Credits Includes a Live Web Event on 02/18/2026 at 1:00 PM (EST)

    This session will discuss RYSTIGGO® (rozanolixizumab-noli), a subcutaneous infusion that blocks neonatal Fc receptor (FcRn), in the management of adults with anti-acetylcholine receptor (anti-AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive (Ab+) generalized myasthenia gravis (gMG). Within the evolving gMG treatment landscape, understanding its clinical application is key to supporting shared decision-making that aligns with patients’ unique needs and preferences. Learners will explore best practices for RYSTIGGO administration and review recent data from the Phase 3 MycarinG and extension studies. In this session, we will apply clinical insights to a patient case and explore practical strategies for incorporating RYSTIGGO into treatment plans for adults with anti-AChR or anti-MuSK Ab+ gMG.

    image

    This session will discuss RYSTIGGO® (rozanolixizumab-noli), a subcutaneous infusion that blocks neonatal Fc receptor (FcRn), in the management of adults with anti-acetylcholine receptor (anti-AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive (Ab+) generalized myasthenia gravis (gMG). Within the evolving gMG treatment landscape, understanding its clinical application is key to supporting shared decision-making that aligns with patients’ unique needs and preferences. Learners will explore best practices for RYSTIGGO administration and review recent data from the Phase 3 MycarinG and extension studies. In this session, we will apply clinical insights to a patient case and explore practical strategies for incorporating RYSTIGGO into treatment plans for adults with anti-AChR or anti-MuSK Ab+ gMG.

    Learning Objectives: At the conclusion of this session, learners will be able to: 

    • Apply best practices for the administration of RYSTIGGO
    • Analyze and interpret recent clinical trial data for RYSTIGGO in adults with anti-AChR or anti-MuSK Ab+ gMG
    • Personalize treatment strategies and goals using a patient case with gMG to foster critical thinking

    Deena Rodney, MSN, APRN, ATC, AQH

    Deena M. Rodney, MSN, APRN, ATC, AQH, started her nursing career as a bedside neurology and psychiatric nurse. Shortly into her career, she transitioned to a unit educator for the neuroscience department (neurology medicine, surgical, and intensive care unit [ICU]). She found her strength in educating and grew into an administrator position developing graduate nurse programs for specialty units and training preceptors. Ms Rodney also held her roots to neurology, and post-graduate, accepted her current position of 16 years as community neurology APRN, caring for general neurology patients and rounding at one of the largest hospitals in central Florida. As she honed her profession, she developed a strength in care for the neuromuscular patient. In her practice, Ms Rodney is able to manage all aspects of patient care, including involvement in research and monitoring patients in the infusion suite. She has a mutual passion to care for the whole person and to educate providers.

    CRNI® RUs: This session has been approved for 2 CRNI® recertification units and meets the non INS Meeting criteria.

    Contact Hours: This session has been approved for 1 contact hour

    Expiration date for receipt of contact hours: February 18, 2029

    To receive contact hours for this educational activity, you are required to attend the entire educational activity and complete the evaluation.

    The Infusion Nurses Society is approved as a provider of continuing nursing education by the California Board of Registered Nursing, provider #CEP14209. The certificate must be retained by the attendee for a period of 4 years.

  • Advancing Infusion Safety Through Smart Pump EHR Interoperability
    Contains 3 Component(s), Includes Credits Includes a Live Web Event on 01/29/2026 at 1:00 PM (EST)

    This session examines how smart pump–electronic health record (EHR) interoperability improves infusion safety, accuracy, and workflow efficiency. Participants will explore how bidirectional data exchange between pumps and EHRs reduces manual programming errors and enhances clinical decision-making. The discussion will highlight key technical and clinical components that support safe, reliable integration, along with real-world outcomes demonstrating error reduction and workflow optimization. Common challenges, such as data mapping, validation, and user adoption will be addressed, with practical strategies for overcoming them. Attendees will also learn how to use interoperability data and continuous quality improvement (CQI) methods to monitor performance and drive ongoing safety improvements. By the end of the session, participants will gain a clear understanding of how to implement, sustain, and optimize interoperable infusion systems.

    image

    This session examines how smart pump–electronic health record (EHR) interoperability improves infusion safety, accuracy, and workflow efficiency. Participants will explore how bidirectional data exchange between pumps and EHRs reduces manual programming errors and enhances clinical decision-making. The discussion will highlight key technical and clinical components that support safe, reliable integration, along with real-world outcomes demonstrating error reduction and workflow optimization. Common challenges, such as data mapping, validation, and user adoption will be addressed, with practical strategies for overcoming them. Attendees will also learn how to use interoperability data and continuous quality improvement (CQI) methods to monitor performance and drive ongoing safety improvements. By the end of the session, participants will gain a clear understanding of how to implement, sustain, and optimize interoperable infusion systems.

    Learning Objectives: At the conclusion of this session, learners will be able to: 

    • Understand the role of smart pumps in enhancing infusion safety
    • Recognize the benefits and challenges of interoperability with clinical systems
    • Explain how smart pump EHR interoperability enhances infusion safety and workflow efficiency
    • Identify key technical and clinical components of interoperable infusion systems
    • Summarize current evidence and outcomes from interoperability implementations
    • Recognize common challenges and strategies for maintaining safe, reliable integration
    • Utilize data and CQI methods to monitor and improve interoperable infusion practices
    • Identify best practices for drug library programming and maintenance

    Sheryl Krause, PhD, RN, CEN, ACNS-BC

    Sheryl Krause, PhD, RN, CEN, ACNS-BC, worked as a bedside nurse in oncology, obstetrics, and the emergency department for 19 years before becoming a clinical nurse specialist (CNS) in the emergency department in 2005. As a CNS, Dr Krause is passionate about ensuring that nurses have access to technology that enhances patient safety without disrupting efficient and effective workflows. She completed her PhD in Nursing with a minor in Industrial and Systems Engineering in 2024. The study of human factors in health care informed her thinking about infusion therapy practices. While in the PhD program, she led a project to implement smart pump technology and interoperability. Dr Krause presented the related outcomes at the 2023 International Symposium on Human Factors and Ergonomics in Health Care.

    CRNI® RUs: This session has been approved for 2 CRNI® recertification units and meets the non INS Meeting criteria.

    Contact Hours: This session has been approved for 1 contact hour

    Expiration date for receipt of contact hours: January 29, 2029

    To receive contact hours for this educational activity, you are required to attend the entire educational activity and complete the evaluation.

    The Infusion Nurses Society is approved as a provider of continuing nursing education by the California Board of Registered Nursing, provider #CEP14209. The certificate must be retained by the attendee for a period of 4 years.

  • Optimizing Outcomes: Evidence-Based Approaches to Vascular Access Device Selection
    Contains 3 Component(s), Includes Credits Includes a Live Web Event on 01/28/2026 at 1:00 PM (EST)

    Selecting the appropriate vascular access device is critical when administering high-risk medications. Infusion nurses often face institutional barriers that prevent them from following evidence-based guidelines, leading to patient harm. This session provides an overview of the risks associated with incorrect device selection and introduces the INS 2024 Vesicant List as a tool for guiding safe infusion practices. Learners will explore how decision-making support tools can empower nurses to advocate for appropriate care. In this session, we will examine how clinical judgment, updated guidelines, and technology can work together to improve vascular access outcomes.

    image

    Selecting the appropriate vascular access device is critical when administering high-risk medications. Infusion nurses often face institutional barriers that prevent them from following evidence-based guidelines, leading to patient harm. This session provides an overview of the risks associated with incorrect device selection and introduces the INS 2024 Vesicant List as a tool for guiding safe infusion practices. Learners will explore how decision-making support tools can empower nurses to advocate for appropriate care. In this session, we will examine how clinical judgment, updated guidelines, and technology can work together to improve vascular access outcomes.

    Learning Objectives: At the conclusion of this session, learners will be able to: 
    • Review key factors that influence vascular access device (VAD) selection in clinical practice
    • Understand infusion-related considerations such as solution characteristics, administration methods, and therapy duration
    • Recognize patient and vessel-related risks associated with infusion therapy
    • Utilize educational resources to support informed, evidence-based decision-making for device selection

    Barb Nickel, APRN-CNS, CCRN, CRNI®

    Barb Nickel, APRN-CNS, CCRN, CRNI®, is a Clinical Nurse Specialist at a large health care system in the United States, responsible for staff development and process improvement to optimize outcomes in multiple areas of clinical practice, including critical care, infusion therapy, sepsis, and new graduate transition to practice. Ms Nickel has presented nationally and published in several peer-reviewed journals on infusion-related topics. She was the Chair of the 2024 INS Infusion Therapy Standards of Practice (SOP)Committee, and is now Chair of the 2027 INS SOP Committee. She also serves as Adjunct Research Fellow for Griffith University, Queensland, Australia.

    CRNI® RUs: This session has been approved for 2 CRNI® recertification units and meets the non INS Meeting criteria.

    Contact Hours: This session has been approved for 1 contact hour

    Expiration date for receipt of contact hours: January 28, 2029

    To receive contact hours for this educational activity, you are required to attend the entire educational activity and complete the evaluation.

    The Infusion Nurses Society is approved as a provider of continuing nursing education by the California Board of Registered Nursing, provider #CEP14209. The certificate must be retained by the attendee for a period of 4 years.

  • Integrated vs Non-Integrated Peripheral IV Catheters: Evidence, Application, and Context in Clinical Practice
    Contains 3 Component(s), Includes Credits Includes a Live Web Event on 01/27/2026 at 4:00 PM (EST)

    Peripheral intravenous catheters (PIVCs) are among the most frequently used medical devices, yet the optimal choice between integrated and non-integrated systems is still debated. Despite strong conceptual advantages for integrated designs, real-world evidence has not consistently demonstrated superiority across all clinical contexts. This session will explore current evidence, practical implications, and cost–benefit considerations for device selection. Drawing on recent trials and clinical experience, we will discuss when integrated catheters may offer measurable benefit and when non-integrated devices may perform equally well. Participants will gain tools to interpret the evidence within the context of their own clinical environment and patient population

    image

    Peripheral intravenous catheters (PIVCs) are among the most frequently used medical devices, yet the optimal choice between integrated and non-integrated systems is still debated. Despite strong conceptual advantages for integrated designs, real-world evidence has not consistently demonstrated superiority across all clinical contexts.

    This session will explore current evidence, practical implications, and cost–benefit considerations for device selection. Drawing on recent trials and clinical experience, we will discuss when integrated catheters may offer measurable benefit and when non-integrated devices may perform equally well. Participants will gain tools to interpret the evidence within the context of their own clinical environment and patient population.

    Learning Objectives: At the conclusion of this session, learners will be able to: 
    • Describe the structural and functional differences between integrated and non-integrated PIVCs
    • Discuss current evidence regarding device performance, complications, and cost-effectiveness across different patient populations and care settings
    • Explain how contextual factors, such as insertion site, gauge, expected dwell time, and inserter experience affect PIVC outcomes and the applicability of published findings

    Tricia Kleidon, PhD, MNSc, BNSc

    Tricia Kleidon, Phd, MNSc (Nurse Practitioner), BSc (Nursing), is a Nurse Practitioner in Paediatric Vascular Assessment and Management at Queensland Children’s Hospital and a Research Fellow at The University of Queensland. She works within a dynamic clinical and research team dedicated to improving patient outcomes and reducing vascular access-related complications. Dr Kleidon recently completed her PhD, which focused on techniques and technologies to improve first-time peripheral intravenous catheter (PIVC) insertion success, and reduce complications. She is passionate about the intersection of research and clinical practice and is always up for sharing ideas—preferably over a spritz or 2.

    DJ Shannon, MPH, CIC, VA-BC, AL-CIP, FAPIC

    DJ Shannon, MPH, CIC, VA-BC, AL-CIP, FAPIC, has been involved in infection prevention and infectious diseases for over a decade, with experience spanning research, state public health, academics, and acute care hospitals. With a background in human biology and epidemiology, his focus is on the intersection of antimicrobial resistance, device-associated infections, and infection prevention. Mr Shannon is the 2025 Immediate Past President of Association for Professionals in Infection Control and Epidemiology (APIC) Indiana. He was a clinical reviewer for the 2021 INS Infusion Therapy Standards of Practice and a co-author of the Association for Vascular Access (AVA) Standards of Care for Peripheral Intravenous Catheters. Most recently, he served as the lead author for the APIC Implementation Guide for Preventing Catheter-Associated Bloodstream Infections (CABSIs) in Adults.

    CRNI® RUs: This session has been approved for 2 CRNI® recertification units and meets the non INS Meeting criteria.

    Contact Hours: This session has been approved for 1 contact hour

    Expiration date for receipt of contact hours: January 27, 2029

    To receive contact hours for this educational activity, you are required to attend the entire educational activity and complete the evaluation.

    The Infusion Nurses Society is approved as a provider of continuing nursing education by the California Board of Registered Nursing, provider #CEP14209. The certificate must be retained by the attendee for a period of 4 years.

  • Immediate-Use Compounding
    Contains 3 Component(s), Includes Credits Recorded On: 12/10/2025

    As health-care professionals, we are entrusted with making sure that every compounded sterile preparation (CSP) is accurate and carries the lowest possible risk of contamination. It is preferred that CSPs are prepared in a pharmacy’s ISO-5 compounding suite. However, there are occasions when patient needs require us to prepare medications outside of those controlled settings. This course will take an in-depth look at the minimum requirements as well as the best practices for maintaining patient safety when sterile drugs are mixed in environments outside of a cleanroom.

    image

    As health-care professionals, we are entrusted with making sure that every compounded sterile preparation (CSP) is accurate and carries the lowest possible risk of contamination. It is preferred that CSPs are prepared in a pharmacy’s ISO-5 compounding suite. However, there are occasions when patient needs require us to prepare medications outside of those controlled settings. This course will take an in-depth look at the minimum requirements as well as the best practices for maintaining patient safety when sterile drugs are mixed in environments outside of a cleanroom. 

    Learning Objectives: At the conclusion of this session, learners will be able to: 
    • Define immediate-use compounding under USP <797> (2023)
    • Identify and understand the seven criteria that qualify preparation as an immediate-use CSP, exempting it from full USP <797> requirements
    • Describe best practices for reducing the risk of contamination when compounding for immediate use outside of ISO-5 conditions
    • Explain the distinction between compounding and preparation by approved labeling

    Maegan Brehm, PharmD

    Maegan Brehm, PharmD, is a Clinical Operations Pharmacist with WeInfuse and RxToolKit, where she promotes clinical safety initiatives. Dr Brehm graduated from the University of Nebraska Medical Center and began her career managing a high-volume retail pharmacy. She then transitioned to sterile compounding and home infusion care at Option Care Health and later to a critical access hospital in Nebraska. Her current work includes developing clinical competencies and RxWorkflow tools through RxToolKit and providing expert advice and real-world insight to the WeInfuse software engineering team. Dr Brehm brings over 12 years of experience in infusion therapy, sterile compounding, and staff education. She has a passion for improving patient safety, mentoring learners, and translating complex standards into practical solutions.

    CRNI® RUs: This session has been approved for 2 CRNI® recertification units and meets the non INS Meeting criteria.

    Contact Hours: This session has been approved for 1 contact hour

    Expiration date for receipt of contact hours: December 10, 2028

    To receive contact hours for this educational activity, you are required to attend the entire educational activity and complete the evaluation.

    The Infusion Nurses Society is approved as a provider of continuing nursing education by the California Board of Registered Nursing, provider #CEP14209. The certificate must be retained by the attendee for a period of 4 years.